Spine · 2026
Precocious Puberty as a Significant Risk Factor for Scoliosis: A Retrospective Cohort Study Demonstrating Synergistic Effects of GnRHa Therapy and Protective Role of Vitamin D.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Shuhao, Li Xiang, Wu Yurui, Chen Yuli, Jin Shuqing, Huang Chongan, Wang Xiangyang
Аннотация
STUDY DESIGN: Cross-sectional and retrospective cohort study.
OBJECTIVE: This study aimed to investigate the impact of precocious puberty (PP) on scoliosis development and to evaluate the effects of gonadotropin-releasing hormone agonist (GnRHa) therapy and vitamin D (VitD) supplementation.
SUMMARY OF BACKGROUND DATA: The effects of precocious puberty, GnRHa therapy, and VitD supplementation on scoliosis remain unclear.
METHODS: The cross-sectional analysis included 5605 participants, while the retrospective cohort comprised 1575 individuals. Data on PP diagnosis, GnRHa therapy, VitD supplementation were obtained from medical records. Scoliosis was radiographically defined as a Cobb angle ≥10°. Logistic and Cox regression models were used in cross-sectional and cohort analyses, respectively, to assess the associations of PP and GnRHa therapy with scoliosis incidence.
RESULTS: In the cross-sectional study, scoliosis prevalence was higher in the PP group compared with controls (19.2% vs. 5.6%, P <0.001), yielding an adjusted odds ratio (OR) of 3.92. Vitamin D deficiency further increased scoliosis risk (HR=2.04, P =0.003). In the longitudinal cohort, PP was associated with a 5.44-fold elevated risk of de novo scoliosis. GnRHa therapy independently increased scoliosis risk (HR=1.99, P =0.004). Conversely, VitD supplementation reduced scoliosis incidence by 51.5% among GnRHa-treated patients (HR=0.43, P <0.001). A U-shaped biphasic association was observed between estradiol levels and scoliosis risk (non-linear P <0.05).
CONCLUSION: PP and GnRHa therapy synergistically increase scoliosis risk, whereas VitD co-therapy mitigates this effect. Baseline spinal surveillance and VitD supplementation are recommended for PP patients initiating GnRHa therapy.
LEVEL OF EVIDENCE: 3.
OBJECTIVE: This study aimed to investigate the impact of precocious puberty (PP) on scoliosis development and to evaluate the effects of gonadotropin-releasing hormone agonist (GnRHa) therapy and vitamin D (VitD) supplementation.
SUMMARY OF BACKGROUND DATA: The effects of precocious puberty, GnRHa therapy, and VitD supplementation on scoliosis remain unclear.
METHODS: The cross-sectional analysis included 5605 participants, while the retrospective cohort comprised 1575 individuals. Data on PP diagnosis, GnRHa therapy, VitD supplementation were obtained from medical records. Scoliosis was radiographically defined as a Cobb angle ≥10°. Logistic and Cox regression models were used in cross-sectional and cohort analyses, respectively, to assess the associations of PP and GnRHa therapy with scoliosis incidence.
RESULTS: In the cross-sectional study, scoliosis prevalence was higher in the PP group compared with controls (19.2% vs. 5.6%, P <0.001), yielding an adjusted odds ratio (OR) of 3.92. Vitamin D deficiency further increased scoliosis risk (HR=2.04, P =0.003). In the longitudinal cohort, PP was associated with a 5.44-fold elevated risk of de novo scoliosis. GnRHa therapy independently increased scoliosis risk (HR=1.99, P =0.004). Conversely, VitD supplementation reduced scoliosis incidence by 51.5% among GnRHa-treated patients (HR=0.43, P <0.001). A U-shaped biphasic association was observed between estradiol levels and scoliosis risk (non-linear P <0.05).
CONCLUSION: PP and GnRHa therapy synergistically increase scoliosis risk, whereas VitD co-therapy mitigates this effect. Baseline spinal surveillance and VitD supplementation are recommended for PP patients initiating GnRHa therapy.
LEVEL OF EVIDENCE: 3.